Life Science World (Free subscription) | 11/06/2009
[NEWS] ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the third quarter ended September 30, 2009 and reviewed its recent accomplishments and upcoming milestones. Novavax's net loss for the third quarter of 2009 was $7.5 million, or $0.08 per share, compared to a net loss of $7.8 million, or $0.12 per share,...
PR News Wire (Free subscription) | 11/06/2009
ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the third quarter ended September 30, 2009 and reviewed its recent accomplishments and upcoming milestones.
Medical News Today (Free subscription) | 11/03/2009
Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine in Healthy Adults" on Saturday, October 31, 2009 at the 47(th) Annual Meeting of the Infectious Diseases Society of America (IDSA).
Miami Herald (Free subscription) | 11/02/2009
Biotechnology company Novavax Inc. said Monday its seasonal flu vaccine candidate met key goals in a midstage clinical trial.
Seattle Post-Intelligencer (Free subscription) | 11/02/2009
ROCKVILLE, Md. -- Biotechnology company Novavax Inc. said Monday its seasonal flu vaccine candidate met key goals in a midstage clinical trial.
Seattle Times (Free subscription) | 11/02/2009
Biotechnology company Novavax Inc. said Monday its seasonal flu vaccine candidate met key goals in a midstage clinical trial.
PR News Wire (Free subscription) | 11/02/2009
ROCKVILLE, Md., Nov. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine in Healthy Adults" on Saturday, October 31, 2009 at the 47(th) Annual Meeting of the Infectious...
San Fransisco Chronicle (Free subscription) | 11/02/2009
(11-02) 06:59 PST Rockville, Md. (AP) -- Biotechnology company Novavax Inc. said Monday its seasonal flu vaccine candidate met key goals in a midstage clinical trial. The company said it presented the results at the 47th annual meeting of the... Clinical trial - Flu season - Health - Influenza - Vaccination
Stock Market Analysis (Free subscription) | 11/05/2009
Below is a list of some of the largest stock gainers and losers so far in pre market for November 5, 2009. Check out my Hot Stocks to Watch page for the latest updates. Pre Market Stock Gainers - 11/5/09 Sunesis Pharmaceuticals Inc. (SNSS) - Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia Parlux Fragrances Inc. (PARL) - Parlux Q2 profit falls ; sees...
